Clinical Trial Update: Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial comparing anlotinib to docetaxel as second-line therapy in EGFR wild-type advanced non-small cell lung cancer; status of the trial is currently un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: Lung Cancer, Lung Cancer Metastatic | Phase 2 | Status: UNKNOWN